Table 2.
The association between the tumor burden and clinical outcomes in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors.
| N | Univariate analysis | Multivariate analysis | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-free survival | Overall survival | Progression-free survival | Overall survival | ||||||||||
| HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | ||
| BNML | |||||||||||||
| One | 42 | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – |
| More | 52 | 1.91 | 1.17–3.12 | 0.010 | 2.58 | 1.38–4.80 | 0.002 | 1.98 | 1.19–3.29 | 0.008 | 2.19 | 1.15–4.18 | 0.017 |
| BSLD | |||||||||||||
| ≤ 28 | 33 | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – |
| > 28 | 61 | 2.17 | 1.27–3.69 | 0.004 | 4.47 | 1.99–10.03 | < 0.001 | 2.57 | 1.44–4.58 | 0.001 | 3.10 | 1.30–7.41 | 0.011 |
| SUVmax | |||||||||||||
| ≤ 12.93 | 23 | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – | 1.00 | – | – |
| > 12.93 | 25 | 2.34 | 1.16–4.70 | 0.017 | 3.65 | 1.46–9.16 | 0.006 | 3.85 | 1.71–8.65 | 0.001 | 1.93 | 0.60–6.25 | 0.271 |
Adjusted by age, sex, Eastern Cooperative Oncology Group performance status. In analysis for overall survival, adjusted also by best overall response for anti-PD-1 monotherapy.
HR hazard ratio, CI confidence interval, BNML the baseline number of metastatic lesions, BSLD the baseline sum of the longest diameters of the target lesions, SUV standardized uptake value.